Fibronostics

About Fibronostics

Fibronostics is a healthcare technology company founded in 2015 by Shleifer Michael Laurent, Ivan Jarry, and Olivier Shleifer, focusing on non-invasive, algorithm-based diagnostics. Headquartered in Orlando, Florida, with origins in Singapore, the firm operates in the diagnostic testing market, specifically targeting the detection and management of chronic metabolic diseases. The company's business model centers on providing its proprietary software-as-a-service (SaaS) platform to healthcare providers, who use it to analyze patient data and generate risk assessments.

The company's core offering, LIVERFASt, is a non-invasive diagnostic tool designed as an alternative to liver biopsies. It utilizes artificial intelligence to analyze 10 biomarkers from a simple blood draw, combined with patient anthropometrics, to assess and stage liver conditions like steatosis (fat), inflammatory activity, and fibrosis (scarring). This provides physicians with crucial data for diagnosing and monitoring diseases such as Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH). The American Medical Association has granted LIVERFASt a Current Procedural Terminology (CPT) code, facilitating its commercialization and reimbursement in the United States. Fibronostics is also preparing for FDA submission after completing its clinical trial data acquisition phase.

Another product, HealthFACTR, is a digital risk assessment tool that evaluates a patient's 10-year risk for chronic conditions including coronary heart disease, stroke, diabetes, and liver disease. By analyzing data from a health questionnaire, clinician assessment, and blood draw, HealthFACTR delivers personalized risk scores and actionable recommendations for mitigation. Fibronostics generates revenue by selling these diagnostic solutions to physicians and healthcare systems, either directly or through strategic partnerships with laboratory service providers like Stone Diagnostics. The company has secured a total of $14.5 million in Series A funding across two rounds, with investments from firms such as AT Capital Group, Elev8, and SPRIM Global Investments, to support commercialization in the U.S. and further research and development into new products for kidney and lung diseases.